Higher incidence of delayed methotrexate clearance in pediatric acute lymphoblastic leukemia patients treated with imatinib

Background: Pediatric patients with Philadelphia chromosome positive (Ph+) or ABL-class fusion positive acute lymphoblastic leukemia (ALL) are currently treated with the tyrosine kinase inhibitor (TKI) imatinib added to a chemotherapy backbone that also contains several courses of high-dose methotre...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Inge M. van der Sluis, Nikita D. van Dijk, Leiah J. Brigitha, Freya M. Steinhauer, Rob Pieters
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2023-12-01
Serija:	EJC Paediatric Oncology
Teme:	Acute lymphoblastic leukemia Imatinib High-dose methotrexate Clearance Pediatric
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2772610X23001113
Oznake:	Označite Brez oznak, prvi označite!